On January 6, 2023, the Food and Drug Administration approved the new Alzheimer’s drug lecanemab, which has been shown in clinical trials to slow cognitive decline in patients with mild cognitive impairment or early Alzheimer’s disease. The approval offers patients renewed hope after repeated failures to find effective treatments. The announcement came following a highly […]
National Coverage Determination Analysis on Treatment for Alzheimer’s Disease
CMS NEWS (released on 7/12/2021 by CMS) CMS Opens National Coverage Determination Analysis on Treatment for Alzheimer’s Disease Thorough Process Will Enable Careful Consideration of Coverage and Incorporate Public Input Today, the Centers for Medicare & Medicaid Services (CMS) is opening a National Coverage Determination (NCD) analysis, a process that will allow the agency to […]
FDA Approves New Alzheimer’s Drug—But Does it Work?
Q. My family has a history of Alzheimer’s disease. We heard that a new drug for Alzheimer’s was just approved by the FDA. The process for its approval seemed kind of fast and it seems that Alzheimer’s drugs in the past have been unsuccessful. Could this one be different? Should people with Alzheimer’s and their […]